# Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial

> **NCT01887561** · PHASE2 · UNKNOWN · sponsor: **Kanto CML Study Group** · enrollment: 100 (estimated)

## Conditions studied

- Myelogenous Leukemia, Chronic, Chronic Phase

## Interventions

- **DRUG:** dasatinib

## Key facts

- **NCT ID:** NCT01887561
- **Lead sponsor:** Kanto CML Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-11
- **Primary completion:** 2012-12
- **Final completion:** —
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2013-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01887561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01887561, "Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01887561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*